ASX Announcement

26 August 2026

BCAL Takes Interest in Genetic Signatures to 18.46%

Highlights

- **BCAL has acquired 18.75m shares (8.25%) in Genetic Signatures Ltd for cash of $1.5 million, or 8.0 cents per share**
- **Acquisition brings BCAL's holding to 18.46%**
- **BCAL is interested in using Genetic Signatures tech to broaden its own diagnostic platform and provide future growth optionality**

BCAL Diagnostics Limited (ASX: BDX), an Australian healthcare company pioneering diagnostics for early detection of cancer, has acquired approximately 8.25% of Genetic Signatures Ltd (ASX: GSS), bringing its total holding to approximately 18.46%.

Under the transaction, BCAL has acquired 18.75 million Genetic Signatures shares for $1.5 million, at 8.0 cents per share for cash. This brings BCAL's total holding to 41,923,644 shares or 18.46% of Genetic Signatures.

BCAL sees Genetic Signatures as a highly complementary molecular diagnostics company. The strategic rationale for this investment is to broaden and diversify BCAL's diagnostic platform into infectious diseases, leveraging complementary technical capabilities and laboratory facilities, as well as expanded distribution opportunities.

BCAL Non-Executive Chair, Jayne Shaw said "Our increased investment reflects BCAL's conviction in the value of Genetic Signatures' complementary diagnostics technology, and the strategic optionality it gives BCAL to build a stronger, more scalable platform globally."

BCAL CEO, Anne-Louise Arnett said: "We see strategic logic in Genetic Signatures' technology and believe the investment has the potential to create meaningful long-term value for BCAL shareholders. Importantly, our focus remains firmly on business-as-usual operations and driving commercial adoption across our BREASTESTplus™ and Avantect Pancreatic and Ovarian test portfolio."

This announcement has been approved for release by the Board of BCAL. ENDS

For further information:

Anne-Louise Arnett
Chief Executive Officer
aarnett@bcaldiagnostics.com

Jayne Shaw
Non-Executive Chair
Jshaw@bcaldiagnostics.com

About BCAL Diagnostics

BCAL is an Australian company engaged in early cancer detection. BCAL launched its first test BREASTEST*plus*™ as a 'rule-out' test designed to be used in the clinical evaluation of breast disease for women with dense breasts. This is a simple, non-invasive blood test used in conjunction with mammography to improve screening and diagnostic outcomes for breast health.

BCAL also holds exclusive license with ClearNote Health Inc., a US-based precision diagnostics company, for the sale and distribution of Avantect Pancreatic, Avantect Ovarian and Avantect multi-cancer blood tests in Australia and New Zealand.

BCAL is headquartered in Sydney, Australia and listed on the Australian Securities Exchange (ASX: BDX). For more information: https://www.bcaldiagnostics.com/ or contact info@bcaldiagnostics.com.

About Genetic Signature Ltd

Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, 3base®.

Genetic Signatures has released a suite of real-time PCR based products for the routine detection of infectious diseases under the EasyScreen™ brand. This proprietary MDx technology provides hospitals and pathology laboratories with the ability to screen for a wide array of infectious pathogens.